Literature DB >> 20583851

Improved blood pressure control in elderly hypertensive patients: results of the PAPY-65 Survey.

Patricia Van der Niepen1, Alain G Dupont.   

Abstract

BACKGROUND: Blood pressure (BP) control is far from optimal. Studies on factors influencing BP control in the elderly are limited, yet identification of factors contributing to the low rate of BP control is a prerequisite to improvement of clinical management.
OBJECTIVE: To evaluate the rate of BP control and the relationship between different clinical characteristics and BP control in treated hypertensive outpatients aged >or=65 years.
METHODS: The PAPY-65 Survey was a prospective cross-sectional survey conducted in primary care in Belgium in 2007. Participating primary-care physicians were required to include consecutive hypertensive patients aged >or=65 years and treated with antihypertensive drugs. Demographic and anthropometric data as well as data on cardiovascular risk factors and history were obtained. BP was measured in accordance with the European Society of Hypertension/European Society of Cardiology guidelines.
RESULTS: The mean +/- standard deviation (SD) age of the 1272 patients enrolled in the survey was 75 +/- 7 years; 702 (55%) patients were women. The mean +/- SD systolic/diastolic BP was 134/79 +/- 13/8 mmHg. BP was normalized (reduced to <140/90 mmHg, or <130/80 mmHg in patients with diabetes mellitus) in 617 (48.5%) patients overall and in 88 (24%) patients with diabetes (n = 371). The majority of patients (921; 72%) were treated with two or more antihypertensive drugs. Both general obesity (body mass index >or=30 vs <25 kg/m2) and abdominal obesity were associated with lack of BP control (unadjusted odds ratio [OR] 2.988, 95% CI 2.200, 4.057 and OR 2.066, 95% CI 1.649, 2.588, respectively). Abdominal obesity was no longer related to BP control when adjusted for the presence of diabetes. Diabetes was strongly associated with lack of BP control only when a stringent definition of BP control (<130/80 mmHg) was used. The combined presence of subclinical organ damage and a history of cardiovascular disease was associated with less uncontrolled BP (OR 0.62, 95% CI 0.48, 0.80).
CONCLUSION: Compared with previous data in the elderly in Belgium, a clear improvement in BP control was observed, probably related to the use of more antihypertensive agents. The presence of diabetes, excess bodyweight and abdominal obesity were all associated with poor BP control.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20583851     DOI: 10.2165/11537350-000000000-00000

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  46 in total

1.  Aging hearts and vessels: masters of adaptation and survival.

Authors:  Salvatore Pepe; Edward G Lakatta
Journal:  Cardiovasc Res       Date:  2005-05-01       Impact factor: 10.787

2.  Systolic versus diastolic blood pressure and risk of coronary heart disease. The Framingham study.

Authors:  W B Kannel; T Gordon; M J Schwartz
Journal:  Am J Cardiol       Date:  1971-04       Impact factor: 2.778

3.  Global burden of hypertension: analysis of worldwide data.

Authors:  Patricia M Kearney; Megan Whelton; Kristi Reynolds; Paul Muntner; Paul K Whelton; Jiang He
Journal:  Lancet       Date:  2005 Jan 15-21       Impact factor: 79.321

4.  Prevalence, awareness, treatment, and control of hypertension in the elderly: the Three City study.

Authors:  Pauline Brindel; Oliver Hanon; Jean-François Dartigues; Karen Ritchie; Jean-Marc Lacombe; Pierre Ducimetière; Annick Alpérovitch; Christophe Tzourio
Journal:  J Hypertens       Date:  2006-01       Impact factor: 4.844

5.  Differential control of systolic and diastolic blood pressure : factors associated with lack of blood pressure control in the community.

Authors:  D M Lloyd-Jones; J C Evans; M G Larson; C J O'Donnell; E J Roccella; D Levy
Journal:  Hypertension       Date:  2000-10       Impact factor: 10.190

6.  Treatment situation of hypertensive patients in Finnish primary health care.

Authors:  E Kumpusalo; H Pärnänen; J Takala
Journal:  Blood Press Suppl       Date:  1997

7.  Association between blood pressure level and the risk of myocardial infarction, stroke, and total mortality: the cardiovascular health study.

Authors:  B M Psaty; C D Furberg; L H Kuller; M Cushman; P J Savage; D Levine; D H O'Leary; R N Bryan; M Anderson; T Lumley
Journal:  Arch Intern Med       Date:  2001-05-14

8.  Prevalence, awareness, treatment and control of hypertension in Hellas, Greece: the Hypertension Study in General Practice in Hellas (HYPERTENSHELL) national study.

Authors:  Aris D Efstratopoulos; Sofia M Voyaki; Athanasios A Baltas; Filippos A Vratsistas; Dimitrios-Eteoklis P Kirlas; John T Kontoyannis; John G Sakellariou; George B Triantaphyllou; Gregorios A Alokrios; Dimitrios N Lianas; Emanuel A Vasilakis; Kyriakos N Fotiadis; Evangelia E Kastritsea
Journal:  Am J Hypertens       Date:  2006-01       Impact factor: 2.689

9.  Prevalence, awareness, treatment and control of arterial hypertension in an elderly population in Belgium.

Authors:  G De Backer; K Myny; S De Henauw; Z Doyen; H Van Oyen; J Tafforeau; M Kornitzer
Journal:  J Hum Hypertens       Date:  1998-10       Impact factor: 3.012

10.  Why is antihypertensive drug therapy needed in elderly patients with systolodiastolic hypertension?

Authors:  L Thijs; R Fagard; P Lijnen; J Staessen; R Van Hoof; A Amery
Journal:  J Hypertens Suppl       Date:  1994-09
View more
  2 in total

1.  Age and sex disparities in hypertension control: The multi-ethnic study of atherosclerosis (MESA).

Authors:  Nkiru Osude; Ramon Durazo-Arvizu; Talar Markossian; Kiang Liu; Erin D Michos; Michael Rakotz; Gregory Wozniak; Brent Egan; Holly Kramer
Journal:  Am J Prev Cardiol       Date:  2021-08-08

2.  Barriers to achieving blood pressure treatment targets in elderly hypertensive individuals.

Authors:  E K Chowdhury; A Owen; H Krum; L M H Wing; P Ryan; M R Nelson; C M Reid
Journal:  J Hum Hypertens       Date:  2013-02-28       Impact factor: 3.012

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.